Stock Alert: Aldeyra Therapeutics Inc. (ALDX)

(RTTNews) - Shares of Aldeyra Therapeutics Inc. (ALDX) are surging over 18% in pre-market today, after the company announced positive top-line Phase 1 clinical trial results for ADX-629, a first-in-class orally available reactive aldehyde species (RASP) inhibitor in development for the treatment of systemic immune-mediated diseases. Aldeyra also announced Phase 2 clinical development plans for ADX-629.

The stock has been trading between $1.48 - $8.47 in the past one year, and closed Monday's trade at $2.48, up 12 cents or 5.08%. ALDX is currently trading at $2.95, up 47 cents or 18.95% in the pre-market trading session.